PROCÉDÉ PERMETTANT D'ÉVALUER LA TOXICITÉ HÉMATOLOGIQUE D'UN MÉDICAMENT EN COURS D'ÉVALUATION ET MODÈLE PERMETTANT D'ÉVALUER LA TOXICITÉ HÉMATOLOGIQUE D'UN MÉDICAMENT EN COURS D'ÉVALUATION
To provide method for evaluating hematotoxicity of drug to be evaluated, which is excellent in clinical predictability regarding toxicity to the bone marrow, and model for evaluating hematotoxicity of drug to be evaluated.The method for evaluating the hematotoxicity of the drug to be evaluated, the method including: administering the drug to be evaluated to humanized, transgenic NOG mouse, which is obtained by introducing human GM-CSF/IL-3 gene into NOG mouse and the number of human-derived leucocytes in leucocytes in blood thereof is 20% or more； and evaluating that the drug to be evaluated has the hematotoxicity when sample of the humanized, transgenic NOG mouse after the administering the drug to be evaluated is measured for number of cells of human-derived hemocytes, the number of the cells of the human-derived hemocytes is changed compared to control to which vehicle is administered instead of the drug to be evaluated.
